Table 2. Relationship between platelet count and dabigatran-related bleeding in different models.
| N | Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| PLT (×109) | 576 [50] | 1.00 (1.00, 1.01) | 0.768 | 0.95 (0.91, 1.00) | 0.557 | 1.00 (0.99, 1.00) | 0.357 | ||
| PLT count, ×109/L | |||||||||
| <100 | 25 [4] | Reference | Reference | Reference | |||||
| 100–200 | 323 [24] | 0.44 (0.15, 1.27) | 0.131 | 0.34 (0.11, 1.01) | 0.053 | 0.24 (0.08, 0.75) | 0.014 | ||
| ≥200 | 228 [22] | 0.59 (0.20, 1.70) | 0.328 | 0.38 (0.13, 1.16) | 0.106 | 0.26 (0.08, 0.86) | 0.028 | ||
| P for trend | 0.892 | 0.650 | 0.395 | ||||||
| Dichotomous | |||||||||
| <100 | 25 [4] | 1.99 (0.72, 5.54) | 0.185 | 2.81 (0.98, 8.01) | 0.054 | 4.05 (1.32, 12.46) | 0.014 | ||
| ≥100 | 551 [46] | Reference | Reference | Reference | |||||
Model 1: crude model. Model 2: adjusted for age, gender, smoking, drinking, BMI, type of AF. Model 3: as model 2, and additionally adjusted for eGFR, hypertension, CHD, HF, previous stroke or TIA, PAD, history of bleeding, ACEIs/ARBs, beta-blockers, PPIs, amiodarone, digoxin, antiplatelet agents and statins.